Table 2 Adverse Events of 23 PCNSL patients treated with Pen-RMA.
Events, number (%) | Any grade | Grade 1‒2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Hematological toxicities | 17 (73.9) | 15 (65.2) | 2 (8.7) | |
Leukopenia | 11 (47.8) | 9 (39.1) | 2 (8.7) | 0 (0.0) |
Neutropenia | 9 (39.1) | 7 (30.4) | 2 (8.7) | 0 (0.0) |
Anemia | 10 (43.5) | 10 (43.5) | 0 (0.0) | 0 (0.0) |
Thrombocytopenia | 5 (21.7) | 5 (21.7) | 0 (0.0) | 0 (0.0) |
Non-hematological toxicities | ||||
Increased ALT | 8 (34.8) | 8 (34.8) | 0 (0.0) | 0 (0.0) |
Increased AST | 7 (30.4) | 7(30.4) | 0 (0.0) | 0 (0.0) |
Pneumonia | 8 (34.8) | 6 (26.1) | 0 (0.0) | 2 (8.7) |
Renal dysfunction | 6 (26.1) | 4 (17.4) | 2 (8.7) | 0 (0.0) |
irAE | ||||
Myocardial injury | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Rash | 1 (4.3) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
Hypophysitis | 2 (8.7) | 1 (4.3) | 1 (4.3) | 0 (0.0) |
Hypothyroidism | 1 (4.3) | 1 (4.3) | 0 (0.0) | 0 (0.0) |
Hyperthyroidism | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
